EPISODE · Jun 7, 2026 · 4 MIN
今天3分钟我们来聊聊国产首个干细胞药，让造血干细胞移植重症并发症患者生存率从25%飙至65%
from 源于细胞BioInsid的个人播客
国产原研药艾米迈托赛为激素难治型胃肠道aGVHD患者带来曙光。III期临床显示，4周总缓解率63%，近1年生存率65.8%，远超传统治疗25%的2年生存率，且零不良反应，实现免疫调节与组织修复双重功效。 参考文献： 艾米迈托赛注射液关键性III期研究，Stem Cell Research & Therapy，2026 前往小宇宙评论区与主播互动
Embed this episode
Ready to play
今天3分钟我们来聊聊国产首个干细胞药，让造血干细胞移植重症并发症患者生存率从25%飙至65%
0:00
4:41
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
Frequently Asked Questions
How long is this episode of 源于细胞BioInsid的个人播客?
This episode is 4 minutes long.
When was this 源于细胞BioInsid的个人播客 episode published?
This episode was published on June 7, 2026.
Can I download this 源于细胞BioInsid的个人播客 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!